No drugs but instead…..

Alzheimer; News from the web:

The current Alzheimer’s clinical research impasse has encouraged more doctors to pursue non-pharmacological alternatives. For most individuals — beyond the up-to-5-percent who are genetically predisposed to early onset Alzheimer’s — focusing on lifestyle factors as the key to brain fitness and cognitive function, they say, is wiser than waiting for a breakthrough delivered in a pill.

Read all about it HERE

Alzheimer’s predictions

Alzheimer; News from the web:

Heart disease deaths have actually decreased 14 percent since 2000, while Alzheimer’s deaths have increased 89 percent. Of the diseases listed in the 10 leading causes of death in the United States, Alzheimer’s is the only one that can’t be prevented, slowed or cured.

But on the positive side, there is a bloodtest in preparation that will warn you  about 20 ahead of any symptoms.

Read all about it HERE

Disco against Alzheimer’s

Alzheimer; News from the web:

In March 2015, Li-Huei Tsai set up a tiny disco for some of the mice in her laboratory. For an hour each day, she placed them in a box lit only by a flickering strobe. The mice — which had been engineered to produce plaques of the peptide amyloid-β in the brain, a hallmark of Alzheimer’s disease — crawled about curiously. When Tsai later dissected them, those that had been to the mini dance parties had significantly lower levels of plaque than mice that had spent the same time in the dark1.

Read all about it HERE

Watch out with salt!!

Alzheimer; News from the web:

Eating too much salt could increase the risk of Alzheimer’s disease, according to new research.

While the US Department of Agriculture recommends we consume about three-quarters of a teaspoon of salt each day, – equivalent to about eight individual-sized bags of chips – most Americans eat nearly 50 percent more than that on a daily basis.

Experiments on mice and human cells suggest that salty foods trigger an inflammatory immune response that deprives the brain of oxygen and harms neurons, triggering behavioral and mental problems.

Read all about it HERE

Brain muddled after surgery? Now we know why.

Alzheimer; News from the web:

It has been known that people can be disoriented after general anesthesia but now a study found that propofol (a very common drug to use) also disrupts presynaptic mechanisms, probably affecting communication between neurons across the entire brain in a systematic way that differs from just being asleep. In this way it is very different than a sleeping pill

Read all about it HERE

Another promising Alzheimer’s drug

Alzheimer; News from the web:

In a new study, a Salk team found that J147 binds to a protein called ATP synthase, which is responsible for producing a common cellular “energy currency” known as ATP. This protein is known to control aging in worms and flies, and the researchers found that by binding to it the drug was able to prevent age-related damage to the brain.

Read all about it HERE

I want to believe this

Alzheimer; News from the web:

Novel Drug Shows Promising Results in Alzheimer’s Model

  • Scientists report that a novel small-molecule drug, which works by stopping toxic ion flow in the brain that is known to trigger neuronal apoptosis, can restore brain function and memory in a mouse model of Alzheimer’s disease (AD). The team believes the drug could be used to treat AD and other neurodegenerative diseases such as Parkinson’s and amyotropic lateral sclerosis (ALS).

Read all about it HERE

What if you know you’ll have Alzheimer’s some day?

Alzheimer; News from the web:

In 2013, Ms Gregory and a few others started a nonprofit group and created a website (ApoE4.info) where the community could gather. Today the group has more than 2,000 members. They pore over medical journals, reach out to top researchers in the field and share notes about their experiments with diet, exercise and other lifestyle modifications.

Read all about it HERE

Patent law an obstacle for Alzheimer’s solutions

Alzheimer; News from the web:

You would think that all would be working cooperatively towards a solution for Alzheimer’s but this is not the case. The ridiculous costs and time that it takes to run effective tests lead to a short time to recoup your research costs when you would find a workable solution. Researchers can not make a good case that this is a wise investment for Pharmaceutical companies.

So something is really wrong here and the government should look into this.

Read all about it HERE

Chile has a dementia plan

Alzheimer; News from the web:

The government of Chile has adopted a national plan on dementia following consultation with Corporación Alzheimer Chile and other key stakeholders. The plan is the 30th to be adopted worldwide, and includes key targets for improving awareness, access to care, support and treatment, research and risk reduction of dementia by 2025.
It is estimated that 180,000 people are living with dementia in Chile. The plan follows the publication of existing plans in Argentina, Costa Rica, Cuba, Mexico, Puerto Rico, Uruguay and the USA, and includes a budget of USD $5.5m a year for implementation.

Read all about it HERE

Israeli researchers may have found a trigger!

Alzheimer; News from the web:

Dr. Debbie Toiber, of the BGU Department of Life Sciences, and her team discovered that a specific protein — Sirtuin-6 (SIRT6) — is severely reduced in the brains of Alzheimer’s patients. SIRT6 is critical to the repair of DNA, the deterioration of which “is the beginning of the chain that ends in neurodegenerative diseases in seniors,” she explains.

The blood-brain barrier prevents us from simply being able to inject the protein into the brain to replenish its supply. Dr. Toiber is currently working on finding a way to increase the expression of the protein into the brain.

Read all about it HERE

Four trials go to human phase!

Alzheimer; News from the web:

Ionis and Biogen are bringing to bear the Ionis drug technology called antisense, which targets diseases processes at the genetic level. It blocks or modifies production of proteins involved in disease.

The Phase 1/2a study of the Alzheimer’s drug, IONIS-MAPTRx, seeks evidence of safety and signs of activity. It’s to be given in 44 patients with mild Alzheimer’s over three months.The drug targets microtubule-associated tau protein, also called MATP, or tau, an abnormal protein associated with Alzheimer’s.

Read all about it HERE